Roelmi HPC, an innovator in sustainable ingredients for the cosmetic and nutraceutical markets, announced a major expansion with the inauguration of a new legal entity, Roelmi Biotech, and a state-of-the-art production plant.
Located within the Insubria BioPark, Italy’s eighth science and technology park dedicated to biotech, the new facility reportedly marks a significant leap in the company's ability to deliver high-quality biofermented ingredients through precision manufacturing.
Scaling Up White Biotech
The establishment of the Gerenzano facility allows Roelmi HPC to consolidate and integrate its production capacity while upholding rigorous quality standards. According to the company, adopting cutting-edge technologies ensures that its expertise in white biotechnologies can seamlessly transition from laboratory-scale research to full industrial production.
This strategic move is said to reinforce the company’s commitment to environmental stewardship, using processes that respect the planet while meeting the growing global demand for effective, sustainable ingredients.
Rooted in Fermentation
Roelmi Biotech began its journey in 2008 with the development of a proprietary fermentation method for hyaluronic acid metabolites. This breakthrough led to the launch of the PrincipHyal cosmetic line in 2009 using "Full Spectrum Hyaluronans," an approach to generate a broad spectrum of molecular weights working in synergy, mirroring the skin’s natural processes. The technology was subsequently expanded to the nutraceutical sector with the creation of the ExceptionHyal line.
Focused on Circularity and Environmental Stewardship
According to the company, the new hub is entirely focused on fermentation and the circular economy, transforming by-products of Italian industry into valuable new resources to reduce environmental impact.
"The opening of this facility is a source of great pride for us," said Eleonora Santus, general manager of Roelmi Biotech. "It represents a strategic step that strengthens our market presence, enhances the local area, and reaffirms our commitment to sustainable and responsible production."
This inauguration follows the 2022 opening of a dedicated research and development laboratory in Novara, Italy, further solidifying the company's vertically integrated approach to biotechnological innovation.
